Ibrutinib (Imbruvica), developed by the J & J pharmaceutical company is significantly more effective than standard chemotherapy for leukemia.During the trial, some patients with chronic lymphocytic leukemia received ibrutinib, and some patients received chemotherapy. It turned out t...
Ibrutinib stands out for its ability to attack cancer cells with minimal side effects compared to traditional treatments. This aspect has improved the quality of life of many patients, making it a more favorable solution in long-term treatment. Ibrutinib is usually administered orally, killin...